SEP 11, 2026 · PHASE 1/2 TRIAL
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
ClinicalTrials.gov
First-in-human Phase 1/2 dose escalation and expansion study with no reported results; registry record documents planned enrollment and safety endpoints only.
Reported
Planned enrollment320
Study phasePhase 1/2
Primary outcome: Safety and Toler…Through study completion, expected average…